HANSA BIOPHARMA ABHANSA BIOPHARMA ABHANSA BIOPHARMA AB

HANSA BIOPHARMA AB

No trades
See on Supercharts
Market capitalization
‪1.55 B‬SEK
−15.84SEK
‪−831.72 M‬SEK
‪134.09 M‬SEK
‪45.82 M‬
Beta (1Y)
−0.68

About HANSA BIOPHARMA AB

CEO
Søren Tulstrup
Headquarters
Lund
Employees (FY)
168
Founded
2007
ISIN
SE0002148817
FIGI
BBG000QCYH36
Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treat rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR. The company was founded by Lars Björck and Bo Krister Håkansson in 2001 and is headquartered in Lund, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of HNSA is 29.06 SEK — it has decreased by 1.42% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange HANSA BIOPHARMA AB stocks are traded under the ticker HNSA.
HANSA BIOPHARMA AB is going to release the next earnings report on Jul 18, 2024. Keep track of upcoming events with our Earnings Calendar.
HNSA stock is 8.59% volatile and has beta coefficient of −0.68. Check out the list of the most volatile stocks — is HANSA BIOPHARMA AB there?
One year price forecast for HANSA BIOPHARMA AB has a max estimate of 174.00 SEK and a min estimate of 68.00 SEK.
HNSA earnings for the last quarter are −2.40 SEK whereas the estimation was −3.72 SEK which accounts for 35.44% surprise. Estimated earnings for the next quarter are −3.46 SEK. See more details about HANSA BIOPHARMA AB earnings.
HANSA BIOPHARMA AB revenue for the last quarter amounts to ‪50.40 M‬ SEK despite the estimated figure of ‪44.06 M‬ SEK. In the next quarter revenue is expected to reach ‪54.04 M‬ SEK.
Yes, you can track HANSA BIOPHARMA AB financials in yearly and quarterly reports right on TradingView.
HNSA stock has fallen by 2.48% compared to the previous week, the month change is a 2.11% rise, over the last year HANSA BIOPHARMA AB has showed a 42.85% decrease.
HNSA net income for the last quarter is ‪−218.58 M‬ SEK, while the quarter before that showed ‪−124.46 M‬ SEK of net income which accounts for −75.62% change. Track more HANSA BIOPHARMA AB financial stats to get the full picture.
Today HANSA BIOPHARMA AB has the market capitalization of ‪1.55 B‬, it has decreased by 2.53% over the last week.
No, HNSA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, HNSA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HANSA BIOPHARMA AB stock right from TradingView charts — choose your broker and connect to your account.
HNSA reached its all-time high on Oct 4, 2018 with the price of 349.40 SEK, and its all-time low was 2.26 SEK and was reached on Oct 23, 2012.
See other stocks reaching their highest and lowest prices.
As of Apr 19, 2024, the company has 168.00 employees. See our rating of the largest employees — is HANSA BIOPHARMA AB on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HANSA BIOPHARMA AB technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HANSA BIOPHARMA AB stock shows the sell signal. See more of HANSA BIOPHARMA AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on HANSA BIOPHARMA AB future price: according to them, HNSA price has a max estimate of 174.00 SEK and a min estimate of 68.00 SEK. Read a more detailed HANSA BIOPHARMA AB forecast: see what analysts think of HANSA BIOPHARMA AB and suggest that you do with its stocks.